Protagonist Therapeutics (PTGX) Shares Outstanding (2015 - 2026)

Protagonist Therapeutics has disclosed Shares Outstanding across 8 years of filings, most recently posting $64.2 million for Q1 2026.

• Shares Outstanding for Q1 2026 came in at $64.2 million, up 3.71% year-over-year; the trailing twelve-month figure through Mar 2026 was $64.2 million (up 3.71% YoY), and the FY2025 annual result was $62.6 million, up 2.53% from the prior year.
• Shares Outstanding came in at $64.2 million for Q1 2026 at Protagonist Therapeutics, up from $62.6 million in the prior quarter.
• In the past five years, Shares Outstanding ranged from a high of $64.2 million in Q1 2026 to a low of $48.6 million in Q1 2022.
• The 5-year median for Shares Outstanding is $58.7 million (2024), against an average of $57.6 million.
• Across the five-year window, Shares Outstanding grew 18.1% in 2023 and increased 2.21% in 2024, its largest moves.
• Protagonist Therapeutics' Shares Outstanding stood at $49.2 million in 2022, then rose by 17.3% to $57.7 million in 2023, then climbed by 5.76% to $61.0 million in 2024, then advanced by 2.53% to $62.6 million in 2025, then increased by 2.64% to $64.2 million in 2026.
• The last three Shares Outstanding figures came in at $64.2 million (Q1 2026), $62.6 million (Q4 2025), and $62.4 million (Q3 2025), per Business Quant data.